BMS has another Opdivo setback after liver cancer trial failureBristol-Myers Squibb’s cancer immunotherapy Opdivo has suffered another setback after it failed to improve on standard care in Share XBMS has another Opdivo setback after liver cancer trial failurehttps://pharmaphorum.com/news/bms-has-another-opdivo-setback-after-liver-cancer-trial-failure/
R&D Roundup: Novartis pipeline, CRISPR funding and Opdivo disappointmentsNovartis has showcased its pipeline at its annual meet-the-management day, where investors and analysts got to hear company Share XR&D Roundup: Novartis pipeline, CRISPR funding and Opdivo disappointmentshttps://pharmaphorum.com/views-and-analysis/rd-roundup-novartis-crispr-opdivo/
BMS’ Opdivo fails late-stage brain cancer testBristol-Myers Squibb has run into yet another hurdle trying to extend the use of its immuno-oncology blockbuster Opdivo Share XBMS’ Opdivo fails late-stage brain cancer testhttps://pharmaphorum.com/news/bms-opdivo-fails-late-stage-brain-cancer-test/
Keytruda gets okay from FDA for adjuvant melanomaThe US FDA has approved Merck & Co’s Keytruda as an adjuvant treatment for patients with melanoma who Share XKeytruda gets okay from FDA for adjuvant melanomahttps://pharmaphorum.com/news/keytruda-gets-okay-from-fda-for-adjuvant-melanoma/
BMS pulls Opdivo/Yervoy in first-line lung cancerBristol-Myers Squibb (BMS) has run into yet another hurdle as it tries to break into the lucrative first-line Share XBMS pulls Opdivo/Yervoy in first-line lung cancerhttps://pharmaphorum.com/news/bms-pulls-opdivo-yervoy-in-first-line-lung-cancer/
BMS gets new OK for Opdivo/Yervoy in kidney cancerBristol-Myers Squibb has claimed a new approval for its immuno-oncology combination of Opdivo and Yervoy, getting a green Share XBMS gets new OK for Opdivo/Yervoy in kidney cancerhttps://pharmaphorum.com/news/bms-gets-new-ok-for-opdivo-yervoy-in-kidney-cancer/
BMS looks to RNA splicing to boost immunotherapiesBristol-Myers Squibb’s quest to claim dominance in the immunotherapy space continues through a new collaboration with Eisai and Share XBMS looks to RNA splicing to boost immunotherapieshttps://pharmaphorum.com/news/bms-looks-to-rna-splicing-to-boost-immunotherapies/
Merck bags adjuvant okay for Keytruda in melanomaCheckpoint inhibitors have already revolutionised the treatment of advanced melanoma, and Merck & Co has just claimed approval Share XMerck bags adjuvant okay for Keytruda in melanomahttps://pharmaphorum.com/news/merck-bags-adjuvant-okay-for-keytruda-in-melanoma/
Opdivo and Keytruda approved in new lung cancer usesThe FDA has approved Merck’s Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer Share XOpdivo and Keytruda approved in new lung cancer useshttps://pharmaphorum.com/news/bmss-opdivo-approved-lung-cancer/
